1. Home
  2. SCLX vs CURX Comparison

SCLX vs CURX Comparison

Compare SCLX & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$0.57

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Logo Curanex Pharmaceuticals Inc

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$4.41

Market Cap

9.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLX
CURX
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
9.7M
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
SCLX
CURX
Price
$0.57
$4.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 73.1K
7.5K
Earning Date
12-01-2026
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $30,253,000.00
N/A
Revenue This Year
$118.16
N/A
Revenue Next Year
$186.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.54
$0.21
52 Week High
$23.03
$13.33

Technical Indicators

Market Signals
Indicator
SCLX
CURX
Relative Strength Index (RSI) 8.42 38.26
Support Level N/A $4.34
Resistance Level $7.77 $4.71
Average True Range (ATR) 0.17 0.28
MACD -0.04 -0.18
Stochastic Oscillator 2.80 8.05

Price Performance

Historical Comparison
SCLX
CURX

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.

Share on Social Networks: